Literature DB >> 29648575

Early evolutionary divergence between papillary and anaplastic thyroid cancers.

J Capdevila1, R Mayor1, F M Mancuso1, C Iglesias2, G Caratù1, I Matos1, C Zafón1, J Hernando1, A Petit3, P Nuciforo1, J M Cameselle-Teijeiro4, C V Álvarez4, J A Recio2, J Tabernero1,5,6, X Matias-Guiu3,5,7, A Vivancos1, J Seoane1,5,6,8.   

Abstract

Background: Papillary thyroid cancer (PTC) is the most common thyroid carcinoma and exhibits an almost uniformly good prognosis, while anaplastic thyroid cancer (ATC) is less frequent and is one of the most aggressive cancers usually resistant to conventional treatment. Current hypothesis posits that ATC derives from PTC through the progressive acquisition of a discrete number of genomic alterations and implies that the mutational landscape of ATC resembles that of PTC. However, the clinical behaviour of ATC and PTC is radically different. We decided to address the disconnection between the clinical behaviour of ATC and PTC and the proposed model of the progressive development of ATC from PTC. Patients and methods: We carried out exome sequencing of DNA from 14 ATC specimens including three cases of concomitant ATC and PTC as well as their corresponding normal DNA from 14 patients. The sequencing results were validated using droplet digital PCR. We carried out immunohistochemistry and immunofluorescence studies of the concomitant ATC and PTC cases. In addition, we integrated our sequencing results with the existing TCGA data.
Results: Most of the somatic mutations identified in the ATC component differed from the ones in PTC in the cases of concomitant ATC and PTC. The trunks of the phylogenetic trees representing the somatic mutations were short with long branches. In one case of concomitant PTC and ATC specimens, we observed an infiltration of PTC cells within the ATC component. Moreover, we integrated our results with data obtained from TCGA and observed that the most frequent mutations found in ATC presented high cancer cell fraction values and were significantly different from the PTC ones.
Conclusion: ATC diverge from PTC early in tumour development and both tumour types evolve independently. Our work allows the understanding of the relationship between ATC and PTC facilitating the clinical management of these malignancies.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29648575     DOI: 10.1093/annonc/mdy123

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  19 in total

1.  SEOM clinical guideline thyroid cancer (2019).

Authors:  E Gallardo; J Medina; J C Sánchez; A Viúdez; E Grande; I Porras; T Ramón Y Cajal; J Trigo; L Iglesias; J Capdevila
Journal:  Clin Transl Oncol       Date:  2020-01-31       Impact factor: 3.405

2.  Coexisting well-differentiated and anaplastic thyroid carcinoma in the same primary resection specimen: immunophenotypic and genetic comparison of the two components in a consecutive series of 13 cases and a review of the literature.

Authors:  Moira Ragazzi; Federica Torricelli; Benedetta Donati; Alessia Ciarrocchi; Dario de Biase; Giovanni Tallini; Eleonora Zanetti; Alessandra Bisagni; Elisabetta Kuhn; Davide Giordano; Andrea Frasoldati; Simonetta Piana
Journal:  Virchows Arch       Date:  2020-07-18       Impact factor: 4.064

3.  Molecular therapeutics for anaplastic thyroid cancer.

Authors:  Nikita Pozdeyev; Madison M Rose; Daniel W Bowles; Rebecca E Schweppe
Journal:  Semin Cancer Biol       Date:  2020-01-25       Impact factor: 15.707

4.  Primary Versus Secondary Anaplastic Thyroid Carcinoma: Perspectives from Multi-institutional and Population-Level Data.

Authors:  Tam N M Ngo; Trang T B Le; Thoa Le; Andrey Bychkov; Naoki Oishi; Chan Kwon Jung; Lewis Hassell; Kennichi Kakudo; Huy Gia Vuong
Journal:  Endocr Pathol       Date:  2021-09-24       Impact factor: 3.943

5.  Evolution and Impact of Subclonal Mutations in Papillary Thyroid Cancer.

Authors:  Tariq Masoodi; Abdul K Siraj; Sarah Siraj; Saud Azam; Zeeshan Qadri; Sandeep K Parvathareddy; Saif S Al-Sobhi; Mohammed AlDawish; Fowzan S Alkuraya; Khawla S Al-Kuraya
Journal:  Am J Hum Genet       Date:  2019-10-24       Impact factor: 11.025

6.  Epigallocatechin-3-gallate inhibits the growth and increases the apoptosis of human thyroid carcinoma cells through suppression of EGFR/RAS/RAF/MEK/ERK signaling pathway.

Authors:  Dongdong Wu; Zhengguo Liu; Jianmei Li; Qianqian Zhang; Peiyu Zhong; Tieshan Teng; Mingliang Chen; Zhongwen Xie; Ailing Ji; Yanzhang Li
Journal:  Cancer Cell Int       Date:  2019-02-28       Impact factor: 5.722

7.  PD-L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: A retrospective study.

Authors:  Soledad Cameselle-García; Sámer Abdulkader-Sande; María Sánchez-Ares; Gemma Rodríguez-Carnero; Jesús Garcia-Gómez; Francisco Gude-Sampedro; Ihab Abdulkader-Nallib; José Manuel Cameselle-Teijeiro
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967

8.  Global RNA Expression and DNA Methylation Patterns in Primary Anaplastic Thyroid Cancer.

Authors:  Naveen Ravi; Minjun Yang; Nektaria Mylona; Johan Wennerberg; Kajsa Paulsson
Journal:  Cancers (Basel)       Date:  2020-03-13       Impact factor: 6.639

9.  Overdiagnosis of Juvenile Thyroid Cancer: Time to Consider Self-Limiting Cancer.

Authors:  Toru Takano
Journal:  J Adolesc Young Adult Oncol       Date:  2019-10-29       Impact factor: 2.223

10.  Identification of Hub Genes in Anaplastic Thyroid Carcinoma: Evidence From Bioinformatics Analysis.

Authors:  Liqi Li; Mingjie Zhu; Hu Huang; Junqiang Wu; Dong Meng
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.